An observational study in Peripheral T-Cell Lymphoma, sponsored by Associazione Angela Serra per la ricerca sul cancro. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Associazione Angela Serra per la ricerca sul cancro · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Lymphoma, T-Cell, Peripheral with a site in Italy — 6 open to participants now, 8 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · Italy.
Among the 35 studies in Lymphoma, T-Cell, Peripheral with a site in Italy, this one is one of 3 that started in 2018, is one of 2 observational ones, and was the 21st registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →6 of the 35 studies in Lymphoma, T-Cell, Peripheral with a site in Italy are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in Italy, United States, Spain
Ages 18+
Incyte Corporation · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
SecuraBio · Sites in Italy, Belgium, Czechia and 7 more countries
Ages 18+
Xenothera SAS · Sites in Italy, France
Ages 18+
AstraZeneca · Sites in Italy, United States, Australia and 8 more countries
Ages 12+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 21 · Phase 3 5
First in 1997; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 160 across 31 observational studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 82 across the 33 interventional studies, 1,575 across the 2 observational. Of the 27 that completed or were terminated, 14 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 35 have an industry lead sponsor. The 10 most frequent:
Associazione Angela Serra per la ricerca sul cancro is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Associazione Angela Serra per la ricerca sul cancro has 2 studies filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
2 of the studies in Lymphoma, T-Cell, Peripheral with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03964480Associazione Angela Serra per la ricerca sul cancroProspective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | 2026-12-30 |
| NCT06495723Xenothera SASPolyspecific Antibodies in Lymphoproliferative T-cell Disorders | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Lymphoma, T-Cell, Peripheral with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas.
The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL.
The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.
Peripheral T-cell non-Hodgkin lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorder arising from mature T cells of post-thymic origin at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentation. All subtypes are found more commonly in male patients, and the median age at diagnosis is 62 years. This disease is generally associated with high relapse rates and a poor prognosis, with inferior treatment outcomes compared with B-cell lymphomas and have a 5-year-survival \< 32%.
T-cell lymphomas are widely recognized as a complex and heterogeneous group of lymphoproliferative disorders, generally associated with high relapse rates and a poor prognosis. Because of their rarity, they are still very poorly understood.
The introduction of new and more effective therapies and better technologies led the International T-cell non-Hodgkin's Lymphoma Study Group to launch the T-cell Project 2.0 in order to have a contemporary, real-time understanding of the T-cell lymphoma biology and treatment, together with the application of contemporary technologies to further identification of new therapeutic targets.
Per protocol, patients are evaluated according to the treating physician's standard practice. There are no specific evaluations or visits required for the Registry. Data captured in the Registry reflects what is routinely collected for patients with PTCL.
The study plans to collect the tissue sample for central review. The ordinary fixation, cryopreservation and routine tumor cytogenetics are planned for biopsy samples. Chairmen of the Histopathology Review Panel will locate Regional sites where expert hematopathologists will review the material and perform a panel of immunostains (T-cell panel + CD20) and markers not assessed at local site.
Adding of blood sample collection will allow estimating prospectively the frequency of pEBVd detection in our cohort of PTCL patients at baseline and at the end of initial therapy, to characterize agreement between pEBVd and EBER in tumor tissue, and to explore the prognostic or predictive implications of detectable pEBVd in PTCL. Finally, to investigate the genetics and pathogenic mechanisms of aggressive PTCLs on an international scale.
Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma:
Exclusion Criteria:
Diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression-free survival (PFS)
Measured from the date of diagnosis until the date of disease progression or death from T-cell Lymphoma
Time frame: 2 year
Overall Survival (OS)
Measured from the date of diagnosis until death from any cause
Time frame: 3 and 5 year
Progression-Free Survival (PFS)
Measured from the date of diagnosis until the date of disease progression or death from T-cell Lymphoma
Time frame: 3 and 5 years
Event Free Survival (EFS)
Measured from the date of diagnosis until the date of event
Time frame: at 24 months
Complete Response Rate (CR)
Complete response rate at 30 months (CR30) after enrollment (i.e., initiation of treatment)
Time frame: at 30 months
Plan to share: Yes — We plan to share with other involved researchers the minimum information on IPD for publication.
Time frame: Preliminary analysis results will be made available during the study on the single population and separately for each sub-type. Final results will be made available 6-12 months after the end of the study.
Started Oct 2018 (actual). Primary completion is estimated for Dec 2026, 98 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jul 2025 → Dec 2026 and completion Jul 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, T-Cell, Peripheral →
Associazione Angela Serra per la ricerca sul cancro